ClinicalTrials.gg
CompletedNCT05617820Updated Sep 30, 2026Results posted

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

A Phase 3 interventional study of Estradiol and Imvexxy in Dyspareunia, sponsored by Teva Pharmaceuticals USA. Completed at 48 sites in 3 countries. Open to female participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Updated Sep 30, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,050
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Dyspareunia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyspareunia · United States.

Enrollment
Largest of 53
1,050 · median 60
Started
2022
with 1 other
Phase 3
13 of 56
none open now
Registered
49th of 56
by date

Among the 56 studies in Dyspareunia with a site in United States, this one has the largest enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2022, is one of 13 in phase 3, and was the 49th registered.

Dyspareunia

159 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.

Browse Dyspareunia studies →

Open to participants now

8 of the 56 studies in Dyspareunia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Dyspareunia studies recruiting now, 11 (39%) set no upper age limit and 14 (50%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 40 Years to 75 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Dyspareunia with a site in United States, or all of them as a file.
02

Study summary

Randomized, double-blind, placebo-controlled, parallel-designed, multiple-site, bioequivalence study with clinical endpoints.

03

Conditions studied

  • Dyspareunia

Browse trials for

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed, IRB approved that meets all criteria of current FDA and local regulations.
  2. Females aged 40-75 years inclusive who are , with at least:

    1. 12 months of spontaneous amenorrhea (women \<55 year of age with history of hysterectomy without bilateral oophorectomy prior to natural menopause must have Serum follicle-stimulating hormone (FSH) level > 40 mIU/mL); or
    2. 6 months of spontaneous amenorrhea with FSH levels >40mIU/mL; or
    3. At least 6 weeks postsurgical bilateral oophorectomy
  3. Have less than or equal to 5% superficial cells on vaginal cytological smear.
  4. Vaginal pH > 5.0.
  5. Moderate to severe symptom of vaginal pain associated with sexual activity considered the most bothersome vaginal symptom (dyspareunia) of VVA by the patient at screening visit. (i.e., a VVA Symptom Self-Assessment Questionnaire score of 2 or 3) (Appendix B).
  6. Women should be sexually active (for example, have sexual activity with vaginal penetration within approximately one month of screening visit).
  7. Women should anticipate having sexual activity (with vaginal penetration) during the conduct of the study, and agree to at least one episode of sexual intercourse within study days 10-13.
  8. Baseline systolic blood pressure should be no greater than 150 mm Hg and diastolic blood pressure no greater than 90 mm Hg.
  9. Normal mammogram completed within 9 months before randomization and a normal clinical breast examination prior to randomization in the study.
  10. Patients who have underwent complete Hysterectomy, or in the case of patients with an intact uterus (including patients who underwent a partial hysterectomy) the later must have:

    1. A documented papanicolaou (PAP) smear conducted within 12 months before randomization with no findings that the Investigator believes would contraindicate the use of topical vaginal estradiol.
    2. Documented vaginal ultrasonography results within 3 months before randomization to confirm an inactive endometrial lining, defined as endometrial thickness \<4mm.
  11. In the opinion of the Investigator, the patient will comply with the protocol and has a high probability of completing the study.

Exclusion criteria

Exclusion Criteria:

  1. Premenopasual, perimenopausal, pregnant or lactating patient or planning a pregnancy.
  2. Significant history or current evidence of chronic infectious disease, system disorder, organ disorder or other medical condition that in the Investigator's opinion would place the study patient at undue risk by participation or could jeopardize the integrity of the study evaluations.
  3. Any laboratory finding that, in the Investigator's opinion would contraindicate the use of estradiol or compromise patients' safety.
  4. Significant history of cholestatic jaundice, hypertension, coronary heart disease or other serious heart problems, uncontrolled diabetes, hypercholesterolemia, hypercalcemia, hypoparathyroidism, hypertriglyceridemia, systemic lupus erythematosus, renal impairment, residual endometriosis posthysterectomy, asthma, epilepsy, migraine, porphyria, hepatic hemangiomas that in the Investigator's opinion would place the study patient at undue risk by participation or could jeopardize the integrity of the study evaluations.
  5. History of Protein C, Protein S, or antithrombin deficiency, or other thrombophilic disorder.
  6. Patients with known concurrent vaginal infections including but not limited to: Candida albicans, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhea or Gardnerella vaginalis.
  7. Patients with active vaginal herpes simplex infection or have had an outbreak within 40 days before Screening
  8. History of sexual abuse that in the opinion of the investigator may interfere with the patient's assessment of vaginal pain with sexual activity.
  9. Past or current diagnosis of endometrial hyperplasia.
  10. Patients with known, suspected or current history of carcinoma of the breast.
  11. Any patients with past or current undiagnosed vaginal bleeding or significant risk factors for endometrial cancer.
  12. History of estrogen-dependent neoplasia (e.g., endometrial cancer).
  13. Any patients with to estrogens.
  14. Liver impairment or disease or kidney dysfunction or disorder (e.g., chronic renal failure or ).
  15. History of thrombophlebitis, thrombosis, or thromboembolic disorders.
  16. History of cerebrovascular accident, stroke, or .
  17. History of Myocardial infarction or ischemic heart disease.
  18. History or active presence of endocrine disease (except for controlled hypo- or hyper-thyroidism or controlled non-insulin dependent diabetes mellitus). Patients who are on a stable thyroid medication prior to the study should have normal baseline thyroid function test results and expect not to have to change thyroid hormone regimen during the study.
  19. Any clinically significant abnormalities on screening physical exam, assessments, , or laboratory tests such as:

    1. Vulvar or vaginal inflammatory condition such as a contact or allergic dermatitis, lichen sclerosis, or other pathological findings.
    2. Presence of suspicious vulvar or vaginal lesions for dysplasia, , or other pathology other than atrophy.
    3. History of active or chronic pelvic pain.
    4. Painful genital warts or localized areas of ulceration.
    5. Interstitial cystitis.
    6. Unresolved findings suspicious for malignancy on the breast exam; incomplete mammogram result or unresolved findings suggestive of malignant changes or findings requiring follow-up on the pre-study mammogram.
    7. Patients with an intact uterus who have an endometrial thickness of 4mm or greater.
  20. Any prescription treatment for vaginal dryness/irritation within 2 weeks before screening or any over the counter or natural remedies, vaginal lubricants or moisturizers within 1 week before screening.
  21. Taking inducers of such as St. John's wort, anticonvulsants, phenylbutazone, rifampin, rifabutin, nevirapine and efavirenz.
  22. Taking inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, nelfinavir and grapefruit juice.
  23. Fasting triglyceride levels > 350 mg/dL.
  24. History of radiation therapy or recent (within previous 6 weeks) surgical therapy to the vaginal or cervical areas.
  25. Any known or suspected allergies that in the Investigator's opinion would compromise the safety of the patient.
  26. Patients who have used vaginal hormonal products (i.e. rings, creams, gels) within the 4 weeks before Screening.
  27. Patients who have used transdermal estrogen and/or progestin therapy within the 4 weeks before Screening.
  28. Patients who have used oral estrogen, progestin, androgen or selective estrogen receptor modular (SERM) containing drug products within 8 weeks before Screening visit.
  29. Intrauterine progestin therapy within 8 weeks before Screening.
  30. Use of an intrauterine device within 12 weeks before screening visit.
  31. Patients who have used estrogen pellet therapy or progestin implants/ injectable drug therapy within the 6 months before Screening.
  32. Patients who have engaged in sexual intercourse or used vaginal douching within 24 hours of the screening visit.
  33. Inability to understand the requirements of the study and the relative information or are unable or not willing to comply with the study protocol.
  34. Patients who are unable or unwilling to give .
  35. Current history of heavy smoking (more than 15 cigarettes per day) or use of e-cigarettes.
  36. Current use of marijuana.
  37. Recent history of known alcohol or drug abuse, within one year start of the study.
  38. Employees of the Investigator or research center or their immediate family members.
  39. Receipt of any drug as part of a research study within 60 days before Screening.
  40. Previous participation in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,050 participants (actual)

Study arms

  • Experimental
    Estradiol vaginal inserts, 4 mcg

    Estradiol vaginal inserts, 4 mcg. Insert vaginally once daily for 14 days.

    Drug: Estradiol

  • Active comparator
    IMVEXXY® (estradiol vaginal inserts) 4 mcg

    IMVEXXY® (estradiol vaginal inserts) 4 mcg. Insert vaginally once for 14 days.

    Drug: Imvexxy

  • Placebo comparator
    Placebo vaginal inserts

    Placebo vaginal inserts. Insert vaginally once for 14 days.

    Drug: Placebo

Interventions

  • Vaginal Insert, 4 mcg tablet

  • Estradiol 4 mcg Vaginal Insert

  • DrugPlacebo

    Vehicle Vaginal Insert

06

What researchers measure

Primary outcomes

  1. Response Rate (Vaginal Cytology and Vaginal pH)

    % Responders where a "Responder" is defined as a patient with: At least a 25% reduction from baseline in the sum of % basal/parabasal + % intermediate cells on vaginal cytology; and Vaginal pH \< 5.0 with a change from baseline vaginal pH of at least 0.5

    Time frame: 15 days

  2. Change in Most Bothersome Symptom (Dyspareunia)

    Mean change from baseline to Day 15 in dyspareunia score (the self-identified most bothersome symptom in women with VVA). On a scale of 0 to 3, where 0 = none, 1=mild, 2=moderate and 3 = severe

    Time frame: 15 days

Secondary outcomes

  1. Treatment Success in Most Bothersome Symptom

    proportion of patients in each treatment group that are considered a Treatment Success at the end of the treatment period evaluated on Day 15. A "Treatment Success" is defined as a score of 0 or 1 on Day 15 for dyspareunia (the self-identified most bothersome symptom at baseline).On a scale of 0 to 3 where 0 = none, 1=mild, 2=moderate and 3 = severe

    Time frame: 15 days

07

Results

Posted Sep 30, 2026

Participant flow

Participant flow — Overall Study
MilestoneEstradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcgPlacebo Vaginal Inserts
Started353348349
Completed343344346
Not completed1043
Withdrew: Adverse event110
Withdrew: Lost to follow-up302
Withdrew: Non compliance with study drug010
Withdrew: Prohibited medication100
Withdrew: Randomized in error100
Withdrew: Protocol violation110
Withdrew: Withdrawal by subject311

Outcome measures

PrimaryResponse Rate (Vaginal Cytology and Vaginal pH)

% Responders where a "Responder" is defined as a patient with: At least a 25% reduction from baseline in the sum of % basal/parabasal + % intermediate cells on vaginal cytology; and Vaginal pH \< 5.0 with a change from baseline vaginal pH of at least 0.5

Time frame:
15 days
Reported as:
Count of participants · Participants
Response Rate (Vaginal Cytology and Vaginal pH)
ParticipantsEstradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcg
Response Rate (Vaginal Cytology and Vaginal pH)1715
Statistical analysis
  • Estradiol Vaginal Inserts, 4 mcg vs IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg · Difference in % of participants: -0.7 · 90% CI -4.0 to 2.5
PrimaryChange in Most Bothersome Symptom (Dyspareunia)

Mean change from baseline to Day 15 in dyspareunia score (the self-identified most bothersome symptom in women with VVA). On a scale of 0 to 3, where 0 = none, 1=mild, 2=moderate and 3 = severe

Time frame:
15 days
Reported as:
Least squares mean · units on a scale
Change in Most Bothersome Symptom (Dyspareunia)
units on a scaleEstradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcg
Change in Most Bothersome Symptom (Dyspareunia)-1.43 ± 0.049-1.56 ± 0.049
Statistical analysis
  • Estradiol Vaginal Inserts, 4 mcg vs IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg · T/r ratio: 91.6 · 90% CI 85.6 to 97.8
SecondaryTreatment Success in Most Bothersome Symptom

proportion of patients in each treatment group that are considered a Treatment Success at the end of the treatment period evaluated on Day 15. A "Treatment Success" is defined as a score of 0 or 1 on Day 15 for dyspareunia (the self-identified most bothersome symptom at baseline).On a scale of 0 to 3 where 0 = none, 1=mild, 2=moderate and 3 = severe

Time frame:
15 days
Reported as:
Count of participants · Participants
Treatment Success in Most Bothersome Symptom
ParticipantsEstradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcg
Treatment Success in Most Bothersome Symptom220238
Statistical analysis
  • Estradiol Vaginal Inserts, 4 mcg vs IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg · Difference in % of participants: -7.4 · 90% CI -13.6 to -1.3

Adverse events

Collected over 15 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Estradiol Vaginal Inserts, 4 mcg54/349 (15.5%)1/349 (0.3%)54/349 (15.5%)
IMVEXXY® (Estradiol Vaginal Inserts) 4 mcg57/345 (16.5%)0/345 (0%)57/345 (16.5%)
Placebo Vaginal Inserts49/349 (14%)0/349 (0%)49/349 (14%)
Most frequent serious events
Most frequent serious events
EventEstradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcgPlacebo Vaginal Inserts
PancreatitisHepatobiliary disorders1/3490/3450/349
Idiopathic Intercranial HypertensionCardiac disorders0/3490/3450/349
Most frequent other events
Showing 10 of 80
Most frequent other events
EventEstradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcgPlacebo Vaginal Inserts
Administration Site PainGeneral disorders15/34915/34511/349
HeadacheNervous system disorders9/34910/3456/349
Administration Site PruritusGeneral disorders4/3494/3456/349
Administration Site InfectionInfections and infestations3/3495/3452/349
Abdominal DistensionGastrointestinal disorders1/3493/3455/349
Abdominal PainGastrointestinal disorders3/3494/3454/349
Administration Site DischargeGeneral disorders4/3494/3451/349
Administration Sire DiscomfortGeneral disorders0/3494/3453/349
NauseaGastrointestinal disorders2/3493/3450/349
Abdominal DiscomfortGastrointestinal disorders0/3492/3451/349

Baseline characteristics

Although 1050 patients were enrolled, only 1043 administered at least one dose of the investigational product.

Age, Categorical
Age, Categorical(Participants)Estradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcgPlacebo Vaginal InsertsTotal
<=18 years0000
Between 18 and 65 years259266270795
>=65 years907979248
Age, Continuous
Age, Continuous(years)Estradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcgPlacebo Vaginal InsertsTotal
Mean60.3 ± 6.759.5 ± 6.359.5 ± 6.459.7 ± 6.5
Sex: Female, Male
Sex: Female, Male(Participants)Estradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcgPlacebo Vaginal InsertsTotal
Female3493453491043
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Estradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcgPlacebo Vaginal InsertsTotal
Hispanic or Latino234236228698
Not Hispanic or Latino115109121345
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Estradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcgPlacebo Vaginal InsertsTotal
American Indian or Alaska Native0000
Asian891027
Native Hawaiian or Other Pacific Islander0011
Black or African American35352595
White305296308909
More than one race1438
Unknown or Not Reported0123
Postmenopausal Status
Postmenopausal Status(Participants)Estradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcgPlacebo Vaginal InsertsTotal
Natural (Spontaneous Amerorrhea)244260250754
Hysterectomy Without Bilateral Oophorectomy505251153
Bilateral Oophorectomy With or Without Hysterectomy493245126
Other61310
Vaginal Dryness
Vaginal Dryness(Participants)Estradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcgPlacebo Vaginal InsertsTotal
None106622
Mild444146131
Moderate181191191563
Severe114107106327
Vaginal/Vulvur Irritation/Itching
Vaginal/Vulvur Irritation/Itching(Participants)Estradiol Vaginal Inserts, 4 mcgIMVEXXY® (Estradiol Vaginal Inserts) 4 mcgPlacebo Vaginal InsertsTotal
None121118116355
Mild769084250
Moderate10994105308
Severe434344130

3 further baseline measures are reported on the registry.

08

Study locations

48 sites
  • Site 10112
    Birmingham, Alabama 35218, United States
  • Site 10146
    Chandler, Arizona 85224, United States
  • Site 10103
    Sacramento, California 95821, United States
  • Site 10124
    Sacramento, California 95821, United States
  • Site 10135
    San Diego, California 92111, United States
  • Site 10136
    Milford, Connecticut 06460, United States
  • Site 10130
    Edgewater, Florida 32132, United States
  • Site 10123
    Hialeah, Florida 33351, United States
  • Site 10139
    Lake Worth, Florida 33461, United States
  • Site 10115
    Leesburg, Florida 34748, United States
  • Site 10138
    Maitland, Florida 32751, United States
  • Site 10107
    Miami Lakes, Florida 33014, United States
  • Site 10144
    Miami Lakes, Florida 33014, United States
  • Site 10101
    Miami Springs, Florida 33166, United States
  • Site 10106
    New Port Richey, Florida 34652, United States
  • Site 10143
    Oldsmar, Florida 34677, United States
  • Site 10129
    Ormond Beach, Florida 32174, United States
  • Site 10116
    Palm Harbor, Florida 34684, United States
  • Site 10117
    Sarasota, Florida 34239, United States
  • Site 10121
    Sunrise, Florida 33351, United States
  • Site 10140
    Tampa, Florida 33614, United States
  • Site 10119
    West Palm Beach, Florida 33409, United States
  • Site 10113
    Norcross, Georgia 30093, United States
  • Site 10104
    Wichita, Kansas 67226, United States
  • Site 10128
    Marrero, Louisiana 70072, United States
  • Site 10109
    Metairie, Louisiana 70001, United States
  • Site 10122
    New Orleans, Louisiana 70127, United States
  • Site 10105
    Saginaw, Michigan 95821, United States
  • Site 10111
    Las Vegas, Nevada 89128, United States
  • Site 10147
    North Las Vegas, Nevada 89030, United States
  • Site 10126
    Lawrenceville, New Jersey 08648, United States
  • Site 10137
    New Bern, North Carolina 28562, United States
  • Site 10145
    New Bern, North Carolina 28562, United States
  • Site 10134
    Philadelphia, Pennsylvania 19114, United States
  • Site 10102
    Upper Saint Clair, Pennsylvania 15241, United States
  • Site 10110
    North Charleston, South Carolina 29405, United States
  • Site 10118
    Chattanooga, Tennessee 37404, United States
  • Site 10142
    Beaumont, Texas 77701, United States
  • Site 10120
    Fort Worth, Texas 76104, United States
  • Site 10141
    Houston, Texas 77022, United States
  • Site 10108
    Norfolk, Virginia 23502, United States
  • Site 10154
    Seattle, Washington 98105, United States
  • Site 10148
    Santa Tecla, La Libertad Department CP 01501, El Salvador
  • Site 10149
    San Salvador, CP 01101, El Salvador
  • Site 10151
    San Pedro Sula, CP 21102, Honduras
  • Site 10153
    San Pedro Sula, CP 21104, Honduras
  • Site 10150
    San Pedro Sula, CP21104, Honduras
  • Site 10152
    San Pedro Sula, Honduras
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Mar 2024, 16 months.

Results were first posted in Sep 2026, 2 years 6 months after primary completion.

Of 10 phase 3 interventional studies under Dyspareunia, half reached primary completion within 13 months of starting (the median); a quarter within 5 and three quarters within 28. This study's 16 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2022
First posted
Nov 16, 2022
StartActual
Nov 15, 2022
Primary completionActual
Mar 15, 2024
CompletionActual
Mar 15, 2024
Results first posted
Sep 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 30, 2026
Sites
1 site added, 1 site removed
Show site
  • Site 10148 · Santa Tecla, El Salvador
Show 1 removed
  • Site 10148 · Santa Tecla, El Salvador
Sep 30, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedChange in Most Bothersome Symptom (Dyspareunia)Time frame: 15 days
  • ChangedBefore ResponderNow Response Rate (Vaginal Cytology and Vaginal pH)Time frame: 15 days
Sep 30, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedTreatment Success in Most bothersome symptomBothersome SymptomTime frame: 15 days
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Site 10148 · Santa Tecla, El Salvador
    Show 1 removed
    • Site 10148 · Santa Tecla, El Salvador
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedChange in Most Bothersome Symptom (Dyspareunia)Time frame: 15 days
    • ChangedBefore ResponderNow Response Rate (Vaginal Cytology and Vaginal pH)Time frame: 15 days
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedTreatment Success in Most bothersome symptomBothersome SymptomTime frame: 15 days
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05617820
Responsible party
Sponsor
First posted
Nov 16, 2022
Start date
Nov 15, 2022
Primary completion
Mar 15, 2024
Completion
Mar 15, 2024
Results posted
Sep 30, 2026
Last update
Sep 30, 2026

Study contacts

C Dias
study director · Teva Pharmaceuticals USA

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion